I’m pleased to share an update on Hikma’s results and progress in the first half of 2025. We’re continued to successfully execute our strategy with discipline and focus, delivering solid results and building strong momentum for the second half of the year.

Our performance reflects the strength of our company and its diversified global business model. Products across all three of our businesses are contributing to top-line growth, supported by operational excellence and an unwavering commitment to quality.

We've made significant strides in expanding our portfolio and strengthening our pipeline, with 50 new launches in the first half of this year. We’ve also had important product approvals, such as TYZAVAN^{™ -} a new formulation of vancomycin ready-to-use bags, and our first us biosimilar Ustekinumab. These launches and approvals reflect our ongoing focus on R&D and business development which enables us to bring high- quality affordable medicine to patients across all of our markets. strategic Investments are positioning us for long-term success.

The Xellia business acquired last year is fully integrated now, and we're working on expanding our technical capabilities and manufacturing capacity to support future growth. Looking ahead, we are expecting an excellent second half and remain confident in our Group outlook for the full year and beyond. With a strong foundation, a growing pipeline, a clear strategic vision, and our world-class team, Hikma is well positioned to deliver sustainable value for all our stakeholders.

I want to thank all my colleagues at Hikma who make our purpose possible, their dedication is vital ensuring we continue to put better health within reach every day.